CONTEXT: Commercial announcement from PCM trials of the opening of a London office to better serve their decentralised trial offering in Europe. IMPACT: Low READ TIME: 1 min Quality Level Continue Reading
CONTEXT: Commercial announcement – Syneos expands its decentralised trial offering IMPACT: Low READ TIME: 1 min Quality Level Mean [1 – 10]: 3 ” TRIALS & FILINGS Novavax COVID-19 Vax Continue Reading
CONTEXT: Following on from Ciox partnering with HealthVerity back in February 2021, Datavant (fresh from partnering with Biodesix on a lung cancer database) have announced a $7billion deal to combine Continue Reading
CONTEXT: Continuing this years theme of presenting RWR posters alongside traditional RCTs, Teva showed off their AJOVY (fremanezumab-vfrm) treatment for migraine at the American Headache Society annual meeting. Also included Continue Reading
CONTEXT: More evidence of the increasing focus on RWE, with Aetion securing another significant round of funding. The company reports doubling of revenues last year and is planning to expand Continue Reading
CONTEXT: Increased backing for the post-COVID era decentralised clinical trials. Can’t help thinking that this feels like a dot com bubble that will burst when the first major safety concerns Continue Reading
CONTEXT: “Data monetisation in the Med Tech environment”. I have to be honest – I’ve read this article twice and still not entirely sure what this actually means in real Continue Reading
CONTEXT: It seems that having Real-World Data (capitalised for emphasis) alongside your traditional clinical data at a poster presentation now adds weight to the overall message. RWR is the must-have Continue Reading
CONTEXT: Commercial merger announcement. Advise caution with regards to applicability in RWR as the technology platform is heavily clinical research focused. IMPACT: Low READ TIME: 1 min *1. “MUNICH–(BUSINESS WIRE)–XClinical, Continue Reading
CONTEXT: Commercial announcement mirroring the developing trend in pulling together RWE data sources and analytical capabilities in response to the regulatory need for more granularity to assess the safety, health, Continue Reading
